Immune checkpoint inhibitors in infectious disease
Immunological Reviews · 2024-11 · 328 (1) · 350-371
DOI: 10.1111/imr.13388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 09.09.2024. Verfasst von Hannah A D King und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Austra…. Hauptthemen laut MEDLINE: HIV Infections, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Foundation for AIDS Research, NIAID NIH HHS, National Health and Medical Research Council.
Abstract (Originalsprache)
Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD‐1) to induce durable immune‐mediated control of HIV, given that anti‐PD‐1 can restore function to exhausted HIV‐specific T cells and also reverse HIV latency, a long‐lived form of viral infection. We highlight several key studies and future directions of research in relation to anti‐PD‐1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment ( AIDS , 2018, 32, 1491), maintenance ( PLoS Pathog , 2016, 12, e1005761; J Infect Dis , 2017, 215, 911; Cell Rep Med , 2022, 3, 100766) and reversal of HIV latency ( Nat Commun , 2019, 10, 814; J Immunol , 2020, 204, 1242), enhancement of HIV‐specific T cell function ( J Immunol , 2022, 208, 54; iScience , 2023, 26, 108165), and investigating the effects of anti‐PD‐1 and anti‐CTLA‐4 in vivo in people with HIV on ART with cancer ( Sci Transl Med , 2022, 14, eabl3836; AIDS , 2021, 35, 1631; Clin Infect Dis , 2021, 73, e1973). Our future work will focus on the impact of anti‐PD‐1 in vivo in people with HIV on ART without cancer and potential combinations of anti‐PD‐1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- Victorian Infectious Diseases Service, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Sharon R Lewin
Förderung
- The Foundation for AIDS Research
- NIAID NIH HHS
- National Health and Medical Research Council
- National Institute of Allergy and Infectious Diseases
- amfAR, The Foundation for AIDS Research
Zitieren
APA
King, H. A. D., & Lewin, S. R. (2024). Immune checkpoint inhibitors in infectious disease. Immunological Reviews, 328(1), 350-371. https://doi.org/10.1111/imr.13388
Vancouver
King HAD, Lewin SR. Immune checkpoint inhibitors in infectious disease. Immunological Reviews. 2024;328(1):350-371. doi:10.1111/imr.13388
BibTeX
@article{King2024,
author = {King, Hannah A D and Lewin, Sharon R},
title = {Immune checkpoint inhibitors in infectious disease},
journal = {Immunological Reviews},
year = {2024},
volume = {328},
number = {1},
pages = {350--371},
doi = {10.1111/imr.13388}
}
EUVIMED